Meet the 10 Market Stars Behind Millionaire-Making in 2025

8. Grail Inc. (NASDAQ:GRAL)

Grail Inc. soared by 379.5 percent in 2025, with the rally primarily boosted by a combination of bullish analyst ratings and strong confidence for its cancer early detection test kit.

Called Galleri, the tool is a single blood test designed to screen more than 50 types of cancer. In its Pathfinder 2 clinical study for the test kit, the company reported an overall positive predictive value of 61.6 percent, meaning that when Galleri flagged the test as positive, cancer was later confirmed in 61.6 percent of those cases.

Earlier this year, Grail Inc. (NASDAQ:GRAL) earned the backing of the Samsung group for the exclusive distribution of Galleri to South Korea and other key Asian markets, potentially Japan and Singapore.

In line with the collaboration, Samsung likewise acquired a $110 million stake in Grail Inc. (NASDAQ:GRAL), covering shares at a price of $70.05 apiece.

Meanwhile, several analysts have posted an upbeat coverage for Grail Inc. (NASDAQ:GRAL) and Galleri. Canaccord, for its part, issued a “buy” recommendation and a price target of $105 earlier, or 25 percent higher than its previous target of $85, amid the significant progress in the adoption and reimbursement for Galleri.

Morgan Stanley also raised its price target to $110 from $85 previously, while maintaining its “equal weight” rating for the stock.

Grail Inc. (NASDAQ:GRAL) said that it would seek the Food and Drug Administration’s (FDA) pre-market approval for the tool within the first quarter of 2026.